Reduction in operational losses and significant advances in clinical development for AB Science in 2023

AB Science SA announced a reduction in its operating loss of 15.7%, amounting to 13.4 million euros for the year ended December 31, 2023. This financial improvement is coupled with significant progress in their portfolio clinical research, in particular the pursuit of marketing authorization applications for masitinib in the treatment of amyotrophic lateral sclerosis (ALS) to the European Medicines Agency and Health Canada. Additionally, promising results were observed in the phase I/II trial with AB8939 for acute myeloid leukemia.

Regarding clinical development, AB Science also announced the launch of a new research program on masitinib against sickle cell anemia, one of the winners of the sixth call for projects "hospital-university health research" funded by the Program investments for the future. Furthermore, the company continues to strengthen its position in intellectual property, in particular with new patents for masitinib in ALS, mastocytosis, and prostate cancer, validated until 2042.